IL129127A0 - Liquid alendronate formulations - Google Patents

Liquid alendronate formulations

Info

Publication number
IL129127A0
IL129127A0 IL12912797A IL12912797A IL129127A0 IL 129127 A0 IL129127 A0 IL 129127A0 IL 12912797 A IL12912797 A IL 12912797A IL 12912797 A IL12912797 A IL 12912797A IL 129127 A0 IL129127 A0 IL 129127A0
Authority
IL
Israel
Prior art keywords
liquid
alendronate formulations
formulations
liquid alendronate
alendronate
Prior art date
Application number
IL12912797A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL129127A0 publication Critical patent/IL129127A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12912797A 1996-10-04 1997-10-02 Liquid alendronate formulations IL129127A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22
PCT/US1997/015740 WO1998014196A1 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Publications (1)

Publication Number Publication Date
IL129127A0 true IL129127A0 (en) 2000-02-17

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12912797A IL129127A0 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Country Status (20)

Country Link
EP (1) EP1007054A4 (ru)
JP (1) JP2001501222A (ru)
CN (1) CN1238691A (ru)
AU (1) AU723357B2 (ru)
BG (1) BG103306A (ru)
BR (1) BR9712197A (ru)
CA (1) CA2267370A1 (ru)
CZ (1) CZ116999A3 (ru)
EA (1) EA001213B1 (ru)
EE (1) EE03669B1 (ru)
HU (1) HUP0000125A3 (ru)
IL (1) IL129127A0 (ru)
IS (1) IS5012A (ru)
NO (1) NO991569L (ru)
NZ (1) NZ334836A (ru)
PL (1) PL332496A1 (ru)
SK (1) SK42999A3 (ru)
TR (1) TR199900730T2 (ru)
WO (1) WO1998014196A1 (ru)
YU (1) YU17499A (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
EP1937362B1 (en) * 2005-09-16 2013-03-27 Selamine Ltd. Bisphosphonate formulation
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および/または治療のための組成物、その組成物の調製方法およびその使用
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
BR9712197A (pt) 1999-08-31
EE03669B1 (et) 2002-04-15
EP1007054A4 (en) 2000-07-19
AU723357B2 (en) 2000-08-24
NO991569L (no) 1999-06-04
EE9900113A (et) 1999-10-15
NZ334836A (en) 2000-11-24
EA199900352A1 (ru) 1999-08-26
JP2001501222A (ja) 2001-01-30
CA2267370A1 (en) 1998-04-09
TR199900730T2 (xx) 1999-07-21
EA001213B1 (ru) 2000-12-25
HUP0000125A3 (en) 2001-04-28
BG103306A (en) 2000-01-31
CN1238691A (zh) 1999-12-15
HUP0000125A2 (hu) 2000-06-28
IS5012A (is) 1999-03-26
WO1998014196A1 (en) 1998-04-09
SK42999A3 (en) 2000-01-18
CZ116999A3 (cs) 1999-09-15
EP1007054A1 (en) 2000-06-14
AU4644897A (en) 1998-04-24
NO991569D0 (no) 1999-03-30
PL332496A1 (en) 1999-09-13
YU17499A (en) 1999-11-22

Similar Documents

Publication Publication Date Title
GB9715751D0 (en) Formulations
ZA974871B (en) Concentrated liquid formulations.
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
IL127915A0 (en) Thermadol multiple unit formulations
HUP0000829A2 (en) Stable liquid interferon formulations
PL333376A1 (en) Connection cubicle
IL129127A0 (en) Liquid alendronate formulations
AU131347S (en) Spatula
GB9725061D0 (en) Revitalisation formulation
ZA963510B (en) New liquid formulations
GB9706957D0 (en) Formulation
GB9816697D0 (en) Liquid formulations
AU718511C (en) Glyphosate liquid formulations
GB9615628D0 (en) Formulation
ZA989196B (en) Liquid compositions
GB9609203D0 (en) Formulations
GB9621401D0 (en) Liquid steriliser
GB9700541D0 (en) Liquid alendronate formulation
GB9613183D0 (en) Effervescent alendronate formulation
GB9624115D0 (en) Formulations
GB9703099D0 (en) Formulations
GB9703101D0 (en) Formulations
GB9704521D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9406050D0 (en) Formulations